Lyell Immunopharma Inc reports results for the quarter ended June 30 - Earnings Summary

• Lyell Immunopharma Inc LYEL.OQ reported a quarterly adjusted loss of $2.89​​ per share for the quarter ended June 30, higher than the same quarter last year, when the company reported EPS of $-3.60. The mean expectation of three analysts for the quarter was for a loss of $3.58 per share. Wall Street expected results to range from $-4.00 to $-3.08 per share.

• Revenue fell 38.5% to $8.00 thousand from a year ago; analysts expected zero.

• Lyell Immunopharma Inc's reported EPS for the quarter was a loss of $2.89​.

• The company reported a quarterly loss of $42.79 million.

• Lyell Immunopharma Inc shares had risen by 19.7% this quarter and lost 17.3% so far this year.

FORECAST CHANGES

• The mean earnings estimate of analysts had fallen by about 3.4% in the last three months.​

• In the last 30 days, one analyst negatively revised an earnings estimate

RECOMMENDATIONS

• The current average analyst rating on the shares is "hold" and the breakdown of recommendations is no "strong buy" or "buy," 1 "hold" and 1 "sell" or "strong sell." The average consensus recommendation for the biotechnology & medical research peer group is "buy."

• Wall Street's median 12-month price target for Lyell Immunopharma Inc is $11.00, about 3.8% above its last closing price of $10.58

This summary was machine generated from LSEG data August 12 at 08:39 p.m. UTC. ​All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)